3 - 5 NOVEMBER 2020 Delivered Digitally

VIEW THE AGENDA

VIEW THE AGENDA

VIEW THE AGENDA

30+ Interactive VIP Access NEW SPEAKERS SESSION PASS FOR IN 2020 FORMATS PHARMA Special Offer for & BIOTECH China Pharmaceutical & Knowledge Partners: Biotech Companies* Brought to you by:

www.biopharmaproduction.com CHINA & GLOBAL BIOPHARMA EXPERTS NEW NEW NEW NEW Dr. Song Rulin Liu Xun Zhang Yu Executive President, China Dr. Chris Chen President, Biomedicine President and CEO, Pharmaceutical Innovation and Chief Executive Officer, Development and Business Division, Aeon Therapeutics, China Research Development Association WuXi Biologics, China Jiangsu Hengrui Medicine, China (PhIRDA), China

NEW NEW NEW Dr. Orit Aharonovitz Li Jing Rong Lisa Zheng Zhang Zhe Ru Senior Vice President, Product Senior Director, Cell Line & Executive Director, Cell Line President, Head of CMC and Development and Manufacturing, Process Development, Teva Development, Transcenta, China Manufacturing, I-MAB Biopharma, CStone Pharmaceuticals, China Pharmaceuticals, Israel China

NEW NEW Dr. Zhu Jianwei NEW NEW Professor and Director of MOE Lynn Yang Yin Nan Po Engineering Research Center of Cell Jerry Su Managing Director, Sequoia Capital, Director, Asia Supply Chain, Amgen, Engineering and Antibody, Shanghai Chief Executive Officer, China China Jiaotong University; CEO and Chief Zhejiang Huahai Biopharmaceuticals Scientist, Jecho Biopharmaceuticals, China NEW NEW NEW NEW John Zhang Dr. Kerstin Otte Yi Jizu Vice President, Manufacturing Professor, Institute of Applied Senior Vice President, CMC & Xi Chen Technology and Process Biotechnology, Biberach University Quality Operations, YZY Biopharma, Director, Cell Engineering, Development, BeiGene, China of Applied Sciences, Germany China Qilu Pharmaceuticals, China

NEW NEW NEW NEW

Ma Yuan Hui Dr. Jill Cai James Li David Shao Executive Director, Preclinical Vice President, Biologics Bioprocess Co-Founder and CEO, President, Chief Executive Officer, and Development, WuXi Biologics, JW Therapeutics, China Science, Shanghai HaiHe Yisheng Biopharma, China Pharmaceutical, China China

NEW Glenn Hassan Wu You Ling Dr. Pan Zhiwei Liu Dong Lian Chief Finance Officer, Chief Business Chief Executive Officer, Senior Director, Process Vice President, Manufacturing, Officer, CANbridge Pharmaceuticals, Zhejiang Teruisi Pharmaceuticals, Development, Junshi Pharma, China TOT BIOPHARM, China China China

NEW NEW

Frank Ye Rani Jarkas Liang Tang Dr. Song Zhiwei Senior Vice President, Technical Chairman, Cedrus Investments, Vice President, CMC Management, Principal Scientist, Bioprocessing Operations, Transcenta, China Hong Kong WuXi Biologics, China Technology Institute, Singapore

NEW NEW NEW

Fu Wei Eric Chang Bao Cai Dr. Karen Liu Chief Executive Officer, CBC Group, Head, Cell Line Development, Senior Director, Manufacturing, Founding Partner, 3E Bioventures China JHL Biotech, China Bio-Thera Solutions, China Capital, China

www.biopharmaproduction.com CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020 DAY 2, WEDNESDAY 4 NOVEMBER 2020 DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks 16.00 Online Networking & Stretch Break 13.00 Chairperson’s Opening Remarks 15.30 CRISPR in Cell Line Development: 13.00 Chairperson’s Opening Remarks 15.50 Accelerating CLD for Commercial Success Applications of CRISPR in Rapid Development of Stable Dr. Pan Zhiwei, Senior Director, Process Development, JOINT OPENING PLENARY JOINT OPENING PLENARY 16.20 Efficient Cell Lines and Technology Applications JOINT OPENING PLENARY Transgene CHO Cell Lines Junshi Pharma, China Joint Plenary Sessions with 10th Annual Biomanufacturing and Joint Plenary Sessions with 10th Annual Biomanufacturing and Joint Plenary Sessions with 10th Annual Biomanufacturing and Lisa Zheng, Executive Director, Cell Line Development, Dr. Zhu Jianwei, Professor and Director of MOE 2nd Annual Cell & Gene Therapy Manufacturing 2nd Annual Cell & Gene Therapy Manufacturing 16.20 Online Networking & Stretch Break 2nd Annual Cell & Gene Therapy Manufacturing Transcenta, China Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief 13.10 Manufacturers’ Panel: 13.10 KEYNOTE ADDRESS 13.10 KEYNOTE ADDRESS Scientist, Jecho Biopharmaceuticals, China 16.40 Using CHO to Develop Biosimilars from Non-CHO Host 16.50 Developing a New CLD Process from Ground-Up New Therapies, New Tech and New Investments China’s Biopharma Capital Markets – Future Funds and Cell Line China’s Big Leap Towards BioPharma 2030 – Innovation, • Navigating the complex landscape of strategies for • New frontiers in drug development Innovative Financing 16.00 Online Networking & Stretch Break Eric Chang, Head, Cell Line Development, JHL Biotech, Industrialization, Internationalization generating new cell lines • What is the gap in quality and investment? Fu Wei, Chief Executive Officer, CBC Group, China China Dr. Song Ru Lin, Executive President, China • Embracing new tech and start-ups to drive progress • From DNA to lead clones, what new technologies 16.20 Advances in Single-Cell Genomics and RNA Sequencing Pharmaceutical Innovation and Research Development • New therapeutics manufacturing, commercialisation 13.40 Venture Capitals Roundtable: and core instrumentation may impact future protein Tools for Effective CLD* 17.10 A Fully Integrated Platform Approach for Highly-Quality Association (PhIRDA), China and global access Show Me the Drug CLD expression and cell line development campaigns? Session Reserved for Namocell • Biomanufacturing 4.0 – Where are we at? • Investment landscape of Chinese biopharma market • Case study in Henlius’ in-house capabilities across Mark Stockdale, Amalgamator of Business and Biology, • DAL’s GAMP and licensing laws – How is it affecting • Evaluating drug pipelines and development prospects the entire biologics value chain spanning across: 13.40 KEYNOTE ADDRESS Solentim, U.K. 16.50 Next-Generation Cell Line Engineering for our business and what we can expect? • Mergers, expansion and JVs – Where do we see - High-titer cell lines; China’s Biological Facilities for the Future – WuXi’s Story Biopharmaceutical Production • The GQCE framework – quality consistency and transactions picking up? - Proprietary cell culture production; and on Technology and Innovation • Advancing microRNA to optimize and boost 17.20 High-Throughput Cloning Screening and Performance better pricing • Financing new plants, new therapeutics, product - Continuous manufacturing process for commercial Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, for Next-Generation Innovative Therapeutics productivity of cell line growth launch and scaling-up operations – How do we production Panelists: China Ting Chen, Director, Alphamab Oncology, China • Use cases and applications of CRISPR/Cas9- review? Senior Representative from Shanghai Henlius Biotech, Jerry Su, Chief Executive Officer, Zhejiang Huahai mediated knockout for enhanced titre • Manufacturing 4.0 – How do VCs and banks play a China 14.10 Online Networking & Stretch Break Biopharmaceuticals, China • Identifying bottlenecks in CLD: a streamlined and part in modernising the value chain? 17.50 Expanding Beyond Traditional Monoclonal Antibodies in Glenn Hassan, Chief Finance Officer, Chief Business high-throughput approach 17.40 Panel Discussion: What’s Next in the Future of CLD&E Cell Line Development Officer, CANbridge Pharmaceuticals, China (tentatively th Dr. Kerstin Otte, Professor, Institute of Applied Panelists: • What is the next thing in medicine that we will need to 9 Annual Cell Line Development & Engineering Asia • Use case for the generation of the highest titer confirming) Biotechnology, Biberach University of Applied Sciences, Rani Jarkas, Chairman, Cedrus Investments, Hong Kong produce? Commences William Cao, Founder, Chairman & CEO, Gracell production cell lines in under 1 week Germany Judith Li, Partner, Lilly Asia Ventures, China • Biotechnologies Group, China A look ATMPs, tissue generation, stem cells, • A look at how pharma is moving cell line development Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, exosomes and more 14.20 Chairperson’s Opening Remarks earlier in the therapeutic development timeline 17.20 Applications for Glycan Analysis Workflows and China 14.00 Online Networking & Stretch Break • The landscape for CRISPR: how ready or willing is the Dr. Orit Aharonovitz, Senior Director, Cell Line & Process • Delivering >99% monoclonality with every campaign Bioanalytical Proteins* Lynn Yang, Managing Director, Sequoia Capital, China industry to use CRISPR for cell line engineering? Development, Teva Pharmaceuticals, Israel Dr. John Zhu, Partner, 6 Dimensions Capital, China through optimizing your CLD workflow 9th Annual Cell Line Development & Engineering Asia Senior Representative from ProZyme • Partnerships and ventures for furthering biopharma Dr. John Proctor, Senior Vice President, Marketing, R&D capabilities and strategies Resumes 14.20 Online Networking & Stretch Break THE STATE-OF-PLAY FOR CLD Berkeley Lights, U.S. 17.50 Industry Panel: Utilising Platform Technologies for CLD 14.20 Chairperson’s Opening Remarks • Navigating the systems and various methods to Moderator: 9 th Annual Cell Line Development & Engineering Asia 14.30 OPENING KEYNOTE accomplish their goals; comparing and contrasting Dr. Song Zhiwei, Principal Scientist, Bioprocessing 18.20 End of Conference Day 1 Resumes Optimising Cell Line Development: Applications for ENGINEERING HOST CELL LINES, GENOMICS tools Technology Institute, Singapore Furthering Biopharma R&D Strategy • Case study-focused & CRISPR IN FOCUS 14.40 Chairperson’s Opening Remarks Panelists: • Partnerships and ventures for furthering biopharma • Dealing with the flow and generation of high- Dr. Song Zhiwei, Principal Scientist, Bioprocessing Dr. Zhu Jianwei, Professor and Director of MOE R&D capabilities and strategies 14.30 Advances in Glycosylation and Expression Vectors for throughput data and information Technology Institute, Singapore • The Biopharma 4.0 paradigm for CLD: digital twins, Engineering Research Center of Cell Engineering and Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Recombinant Proteins applications of big data and tech developments for Antibody, Shanghai Jiaotong University; CEO and Chief Development, Teva Pharmaceuticals, Israel Dr. Song Zhiwei, Principal Scientist, Bioprocessing OPTIMISING WORKFLOWS AND BIOPROCESSES Scientist, Jecho Biopharmaceuticals, China Technology Institute, Singapore cell culture processes Dr. Kerstin Otte, Professor, Institute of Applied 14.50 High-Throughput and Seamless Workflow Automation Biotechnology, Biberach University of Applied Sciences, 15.00 Enhancing Complex Protein Expression with Highly 15.00 Enabling New Frontiers in Recombinant Protein Panelists: in CLD Germany Efficient Gene Integration Technology Therapeutic Development: A Novel and Modular CHO Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Dr. Jill Cai, Vice President, Biologics Bioprocess & Dr. Jill Cai, Vice President, Biologics Bioprocess & Senior Representative from Lonza Expression Platform Development, Teva Pharmaceuticals, Israel Development, WuXi Biologics, China Development, WuXi Biologics, China • Tackling the pressures on the CHO expression system Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, to express complex proteins – new modules for NOVEL ADVANCES IN CLD TECHNIQUES & China 15.20 Integrated Cell Line Development Strategy in Whole 18.20 End of Conference TECHNOLOGY addressing a range of issues such as translation/ Eric Chang, Head, Cell Line Development, JHL Biotech, CMC Picture secretion bottlenecks, lead candidate selection, China • How to evaluate a CHO based expression systems? quality assessment and barcoding of the clonal Lisa Zheng, Executive Director, Cell Line Development, • Can the cell line generation work be integrated with 15.30 Novel Transposases in Accelerating Cell Line production cell line using next generation sequencing Transcenta, China other process? Development • Three case studies illustrating the modular approach • How to achieve cell lines with high quality and stability Dr. Claes Gustafsson, Chief Commercial Officer and for the production of a biosimilar, a vaccine and a under fast workflow? monoclonal antibody 18.30 End of Conference Day 2 Co-Founder, ATUM, U.S. Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, Dr. Igor Fisch, Chief Executive Officer, Selexis, China Switzerland www.biopharmaproduction.com CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020 DAY 2, WEDNESDAY 4 NOVEMBER 2020 DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Opening Address: 13.00 Manufacturers’ Panel: 13.00 Keynote Address: • New IND review procedure 15.50 Online Networking & Stretch Break 15.20 Tech Transfer Development for mAb Manufacturing China’s Big Leap towards BioPharma 2030 – Innovation, New Therapies, New Tech and New Investment Productivity Optimization China’s Biopharma Capital Markets – Future Funds and • Understanding the CMC strategy of biologic Industrialization, Internationalization • New frontiers in drug development • Creating a robust development platform utilizing Innovative Financing development for FDA and NMPA IND Fillings 16.10 China’s Biological Facilities for The Future – Growth, Fu Wei, Chief Executive Officer, CBC Group, China Dr. Ma Yuan Hui, Executive Director, Preclinical Science, Dr. Song Ru Lin, Executive President, China • What is the gap in quality and investment? technologies for scalable and cost-efficient mAb Innovation and Investments Shanghai HaiHe Pharmaceutical, China Pharmaceutical Innovation and Research Development • Embracing new tech and start-ups to drive progress manufacturing process • Understanding Chinese’s bioprocessing capacity – 13.30 Venture Capitals’ Roundtable: Association (PhIRDA), China • New therapeutics manufacturing, commercialization which market and what pipeline • JHL’s efforts to develop a suitable manufacturing Show Me the Drug QUALITY MANAGEMENT & EFFICACY and global access • Challenges and opportunities in innovative drug process and technologies used • Investment landscape in the Chinese biopharma STANDARDS 13.30 Keynote Address: • Biomanufacturing 4.0 – Where are we at? development and manufacturing in China • Case study sharing on Asia’s largest single-use market China’s Biologics Facilities for the Future – WuXi’s Story • DAL’s GAMP and licensing laws – How is it affecting • Insights on growth strategies and how to manage bioprocessing technology-based modular biopharma • Evaluating drug pipelines and development prospects 15.40 Integrated CMC Platforms to Develop Robust on Technology and Innovation our business and what can we expect? • risks associated with geography and product manufacturing facility – how is it being implemented Mergers, expansion and JVs – Where do we see Downstream Process for Clinical Manufacturing Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, • The GQCE framework – Quality consistency and transactions picking up? Dr. Zhang Zhe Ru, President, Head of CMC and development and how has it benefited the manufacturing process China better pricing • Financing new plants, new therapeutics, product Manufacturing, I-MAB Biopharma, China Larry Zhang, Chief Executive Officer, CASI development launch and scaling-up operations – How do we Pharmaceuticals. China Dr. Zack Zheng, Vice President, Process Development, 14.00 Online Networking & Stretch Break Confirmed Panelists: JHL Biotech, China review? 16.10 Online Networking & Stretch Break Jerry Su, Chief Executive Officer, Zhejiang Huahai • Manufacturing 4.0 – How do VCs and banks play a 16.40 Scaling Up the Commercial Production of mAb part in modernising the value chain? 16.30 Ensure Uninterrupted Supply of Biological Drugs 10th Annual Biomanufacturing commences Biopharmaceuticals, China 15.50 Online Networking & Stretch Break Therapeutics in China • Challenges in the biopharma supply chain – long Glenn Hassan, Chief Finance Officer, Chief Business • China’s capacity outlook and how do we capitalize on Moderator: manufacturing lead time, yield variability, testing and BIOMANUFACTURING 2030 – CHINA’S GREAT LEAP Officer, CANbridge Pharmaceuticals, China (tentatively the mAb therapeutics markets INNOVATIVE BIOPROCESS DEVELOPMENT Fu Wei, Chief Executive Officer, CBC Group, China quality assurance, CMC compliance, global footprint, confirming) • Teruisi’s breakthrough of mAb’s tech transfer demand fluctuation 14.20 Trends in Pharma 4.0 Standards and China’s New Drug William Cao, Founder, Chairman & CEO, Gracell and large-scale production in China while in-line 16.10 Glycosylation of Monoclonal Antibody and the Panelists: • Strategical and tactical elements of biopharma supply Delivery Strategy Biotechnologies Group, China Manipulation Rani Jarkas, Chairman, Cedrus Investments, Hong Kong chain management • Demand for capacity drives China’s biomanufacturing with international standards – challenges and key • Glycosylation manipulation + upstream PB-Hybrid Judith Li, Partner, Lilly Asia Ventures, China • Supply chain integration best practices across expansion – is China on the fast track? learnings 14.00 Online Networking & Stretch Break platform + ADC development Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, different functions to cater for global supply • Approval process for biologics – a US-China • Manufacture showcase to improve cost and efficiency Liu Dong Lian, Vice President, Manufacturing, TOT China • Key measures should pharmaceutical companies take comparison Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi th Lynn Yang, Managing Director, Sequoia Capital, China to improve connections with external supply chain 10 Annual Biomanufacturing continues Biopharm, China • QbD and quality matrix for meeting regulatory Pharmaceuticals, China Dr. John Zhu, Partner, 6 Dimensions Capital, China Yin Nan Po , Director, Asia Supply Chain, Amgen, China requirements FUTURE FACILITIES & SMART 16.40 Vaccine Manufacturing Innovation Dr. Liu Xun, President, Biomedicine Development and 17.10 WuXi “Factory of the Future” – A CMC Manufacturing 14.20 Online Networking & Stretch Break 17.00 Biopharma Quality Assurance Best Practices and PAT BIOMANUFACTURING Dr. David Shao, President, Chief Executive Officer, Business Division, Jiangsu Hengrui Medicine, China Case Study Insights • Process development and pilot manufacturing at Yisheng Biopharma, China 10th Annual Biomanufacturing continues • National standards for Chinese biological products 14.20 Manufacturing Technology Showcases – Improving Cost 14.50 Debottlenecking and Process Optimisation in China WuXi Biologics and current challenges in quality management and Efficiency 17.10 C ase Study: • Case study sharing on product stability and quality BioPharma Landscape • Case study sharing on WuXi’s facilities based on GMP IMPLEMENTATION – THE MADE IN CHINA • Next gen manufacturing facilities design and Bio-Works’ 3rd Gen Agarose Resins to Purifying 2025 PLAN assurance during biomanufacturing • Rate-limiting steps in China biopharma’s facilities and disposable technologies investment trends Antibody-based Therapies Using A Different 3-step • Quality system implementation and PAT compliance what are the solutions • Process and quality control best practices upon • Smart automation case studies to increase facility 14.40 Under Chinese New Drug Administration Law and standards – assessment, review and results • Data, complexity and variability in biomanufacturing extensive analytic testing Column Chromatography Approach efficiency and cost optimization New Vaccine Law – Oversight and Implementation Dr. Yi Jizu, Senior Vice President, CMC and Quality • Advances in bioprocess monitoring and analytics, and Dr. Liang Tang, Vice President, CMC Management, WuXi Dr. Bjorn Hammarberg, Business Development Asia, • Intelligent bioreactors – advantages and benefits on Commercial Bioprocess Development and Process Operations, YZY Biopharma, China bioinformatics and computational biology in China Biologics, China Bio-Works, Sweden Frank Ye, Senior Vice President, Technical Operations, Performance Qualification Dr. Simon Hsu, Senior Vice President, Technical Transcenta, China • Industry challenges and opportunities upon the 17.30 Biomanufacturing Process Validation and Quality Risk Operations, Henlius, China 17.40 End of Conference Day 1 17.40 End of Conference Day 2 introduction of Chinese new vaccine law Management • Overview of the manufacturing best practices • New process concepts of CQAs, CPPs, and QbDs 14.50 Manufacturing Technology – From Tech Transfer to Risk 15.20 The New Age of Smart Continuous Manufacturing as and process performance qualification in cGMP • Best practices on quality risk management in Analysis and Migration Strategy Market Moves to Commercial environment bioprocess development • Essential elements of tech transfer and leading to • Optimizing continuous process with fixed stainless- • Process scale-up and optimization within Shanghai • Case study on Bio-Thera’s manufacturing process successful validation and robust commercialization steel facilities Zerun’s commercial production quality control on the newest Humira biosimilar • • Speed-to-market and cost reduction strategies Best practices of a structured risk analysis, quality Dr. John Zeng, Executive Vice President, Product Bao Cai, Senior Director, Manufacturing, Bio-Thera utilizing fully continuous process development management and migration strategy Development and Commercialization, Shanghai Zerun Solutions, China Biotechnology, China • Case study on building a world-class continuous • Case study on BeiGene’s new biologics 18.00 End of Conference Day 3 manufacturing facility and quality system in China manufacturing facility in Guangzhou – technology used from cell line development to manufacturing 15.10 Impact of NMPA Reform on CMC Strategy at IND Stage Dr. Li Jing Rong, Senior Vice President, Product • Dr. John Zhang, Vice President, Manufacturing Regulatory environment before reform – what Development and Manufacturing, CStone are the challenges and how it differs with global Technology and Process Development, BeiGene, China Pharmaceuticals, China standards www.biopharmaproduction.com CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020 DAY 2, WEDNESDAY 4 NOVEMBER 2020 DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Opening Address: Confirmed Panelists: 13.00 Chairperson’s Opening Remarks TECHNOLOGY AND INNOVATION 13.00 Keynote Address: INVESTMENTS AND COMMERCIALISATION China’s Big Leap towards BioPharma 2030 – Innovation, Richard Wang, CEO, Fosun Kite Biotechnology, China China’s Biopharma Capital Markets – Future Funds and Industrialization, Internationalization Dr Zhang Yu, President and CEO, Aeon Therapeutics, 13.00 Manufacturers’ Panel: Innovative Financing 14:20 Developments in Precision Manufacturing and Tailored 14.30 Biotech Investors Roundtable: Financial Incentives, Dr. Song Ru Lin, Executive President, China China New Therapies, New Tech and New Investment Fu Wei, Chief Executive Officer, CBC Group, China Therapies Investments and Pricing Pharmaceutical Innovation and Research Development James Li, Co-Founder and CEO, JW Therapeutics, China • New frontiers in drug development Association (PhIRDA), China More panellists to be confirmed • What is the gap in quality and investment? 13.30 Venture Capitals’ Roundtable: 15:00 Innovations in CAR T-Cell Technology Developments and Panelists: • Embracing new tech and start-ups to drive progress Show Me the Drug Manufacturing Kan Chen, Principal, Qiming Weichuang Venture Capital 13.30 Keynote Address: 15.45 Finding the Market Growth • New therapeutics manufacturing, commercialization • Investment landscape in the Chinese biopharma For speaking enquiry, please contact Management, China China’s Biologics Facilities for the Future – WuXi’s Story Richard Wang, CEO, Fosun Kite Biotechnology, China and global access market [email protected] More panellists to be confirmed on Technology and Innovation • Biomanufacturing 4.0 – Where are we at? • Evaluating drug pipelines and development prospects Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, 16.15 Online Networking & Stretch Break • DAL’s GAMP and licensing laws – How is it affecting • Mergers, expansion and JVs – Where do we see 15:30 Solid Tumors Treatment with TCR-T Generation 15.10 Commercialisation Models and Case studies of CAR-Ts China our business and what can we expect? transactions picking up? Alex Liu, TCR Discovery and Early Development, 16.40 Addressing the Next Wave of Innovations in Cell • The GQCE framework – Quality consistency and • Financing new plants, new therapeutics, product Cytovant Sciences, China CLINICAL TRIALS AND SUPPLY CHAIN 14:00 Online Networking & Stretch Break Therapies better pricing launch and scaling-up operations – How do we James Li, Co-Founder and CEO, JW Therapeutics, China review? 15:00 Online Networking & Stretch Break 15.40 Efficacy Evidence and Clinical Trials – How They 2nd Cell & Gene Therapy Manufacturing commences Confirmed Panelists: • Manufacturing 4.0 – How do VCs and banks play a Affect Product Launch and Outcomes-Based Pricing 17.10 From Liquid to Solid Tumors, from Manual to Automatic Jerry Su, Chief Executive Officer, Zhejiang Huahai part in modernising the value chain? 15:30 Accelerating CAR-T Development and Manufacturing Arrangements CHINA MARKET Manufacturing Biopharmaceuticals, China Yao Shuyuan, General Manager, Wuxi Apptech, China Dr Zhang Yu, President and CEO, Aeon Therapeutics, Glenn Hassan, Chief Finance Officer, Chief Business Moderator: 16.10 Online Networking & Stretch Break 14:20 Chairperson’s Opening Remarks China Officer, CANbridge Pharmaceuticals, China (tentatively Fu Wei, Chief Executive Officer, CBC Group, China 16:15 Developing Cancer Gene Therapy confirming) 16.30 Clinical Drug Development for Cell and Gene Therapies – 14:30 Next Generation Cellular Gene Therapeutics 17.40 Chairperson’s Summary and End of Day 1 William Cao, Founder, Chairman & CEO, Gracell Panelists: 16:45 Use of Adenoviruses for Gene Therapy How Ready Institutions Are? Dr William Cao, Founder, Chairman and CEO, Gracell Biotechnologies Group, China Rani Jarkas, Chairman, Cedrus Investments, Hong Kong Biotechnologies Group, China More panellists to be confirmed Judith Li, Partner, Lilly Asia Ventures, China 17:15 Chairperson’s Summary and End of Day 2 17.00 Case Study of Manufacturing and Supply Chain Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, Challenge 15:00 Industry Panel: 14:00 Online Networking & Stretch Break China Regulatory Pathways for Cell and Gene Therapies in the Lynn Yang, Managing Director, Sequoia Capital, China 17.30 Chairperson’s Summary and End of Day 3 Region, and China 2nd Cell & Gene Therapy Manufacturing commences Dr. John Zhu, Partner, 6 Dimensions Capital, China

14.00 Online Networking & Stretch Break

2nd Cell & Gene Therapy Manufacturing commences

www.biopharmaproduction.com Position your company in the networking heart of this Unrivalled Opportunity to Profile your Company event and create great connection with your attendees

SPONSORS Thought leadership Offer keynotes and educational sessions to you audience AND EXHIBITORS through live webinars or pre-recorded video broadcast with automated reminders, Q & A sessions and polls to keep your GOLD SPONSORS: attendees engaged.

Informa Data+ Unique option for increased lead generation through retargeting of our global proprietary database in social media. BRONZE SPONSOR:

Powerful Digital Matchmaking SPOTLIGHT SPONSOR: Build valuable relationships with our intelligent matchmaking tool, live chat and integrated 1:1 video calls.

EXHIBITORS: Virtual Booths Online spaces with your brand identity, showcase your product demos, live chat with audiences. Manage your own logo, description video, collateral, staff profiles and more.

Focused Metrics Measurable exposure and trackable meetings generate great ROI. Booth views, meeting requests, engagement rates – you’ll have all the data you need.

MEDIA PARTNERS: Accelerated Brand Exposure Gain prominence with focused digital theatres in the lead up, main conference days, and up to 3 months after the event with our on-demand content modules.

For more information on digital sponsorship opportunities, please contact: Yvonne Leong, +65 6508 2489, [email protected]

www.biopharmaproduction.com ABOUT THE EVENT WHO WILL YOU MEET?

BY INDUSTRY: Delivered digitally to help manage travel and physical distancing China/MNC Pharma & Biotech ...... 50% restrictions, the organising committee for 6th BDP China is delighted to CDMOs/CROs/CMOs ...... 25% present an innovative and creative format for the event. Tech Solution Providers ...... 10% Regulators, Healthcare Agencies & Associations ...... 5% Repurposed to address the emerging and likely permanent shifts in Scientific Research & Universities ...... 5% the Chinese biopharma industry, key leaders in the region will convene Others ...... 5% online to discuss investment climate beyond 2020, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains. BY GEOGRAPHY: China ...... 50% With live-streaming sessions, smart networking windows and elevated Japan, Korea, HK, Taiwan ...... 15% exhibition platforms at our virtual BDP China, join us as the industry Southeast Asia ...... 10% convenes at this highly anticipated annual gathering of biopharma USA ...... 10% Europe ...... 10% leaders. Other Region ...... 5%

OUR MARKETING AND 83000+ 76 34000+ DIGITAL MEDIA Unique Countries LinkedIn OUTREACH Pageviews Impressions

www.biopharmaproduction.com AGENDA AT-A-GLANCE

Day 1 of Main Conference | Tuesday, 3 November 2020

KEYNOTE ADDRESS China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization

KEYNOTE ADDRESS China’s Biological Facilities for the Future – WuXi’s Story on Technology & Innovation

• Biomanufacturing 2030 – the hottest shifts in • The state-of-play for cell line development • Maneuvering the Chinese Market for Cell and Gene Therapies manufacturing in China • Applications for furthering biopharma R&D strategy • Addressing the next wave of innovations in cell therapies • Trends in Pharma 4.0 standards and China’s new drug • Novel CLD platform technologies and tools delivery strategy • Industry case studies for high-throughput screening and • Industry case studies for commercial manufacturing performance

Day 2 of Main Conference | Wednesday, 4 November 2020

Manufacturers’ Panel: New Therapies, New Tech & New Investments

• Smarty biomanufacturing and process optimization • Advancements in cell engineering techniques for complex • Managing cost and accelerating manufacturing process • Manufacturing technology showcases – Improving cost and proteins • Latest CAR T-cell technology developments • efficiency CRISPR and genomics in focus • Facilities design and construction call therapies • Innovative bioprocess development • Data-driven, accelerated, and next-generation CLD • Sustainable manufacturing and scalability • Industry Panel: Perspectives on utilising platform technologies for CLD

Day 3 of Main Conference | Thursday, 5 November 2020

KEYNOTE ADDRESS China’s Biopharma Capital Markets – Future Funds & Innovative Financing

Venture Capitals Roundtable: Show Me the Drug

• DAL’s New GAMP and Licensing Law – Implementation and • Optimising workflows and bioprocesses • Investment and commercialisation landscape oversight • Exploring the synergies between engineered host cells and • Case studies on clinical trial landscapes and efficacy evidence • QbD and Quality Matrix for meeting regulatory requirements process development for commercial success • Biomanufacturing process validation and quality risk • Industry Panel: what’s next in the future of CLD&E management • Best practices and strategies in biopharma supply chain integration

www.biopharmaproduction.com 3 - 5 NOVEMBER 2020 Delivered Digitally

WeChat Official Account International Companies – Outside China *International Companies with Global HQ Located Outside China Local China Companies Early Bird Rate Normal Rate Early Bird Rate Normal Rate Register & pay before Register & pay after Register & pay before Register & pay after 11 September 2020 11 September 2020 11 September 2020 11 September 2020

Individual Rate USD 595 USD 695 Individual Rate USD 895 USD 995 Group Rates (Price per Delegate) Group Rates (Price per Delegate) 5 or More USD 495 USD 595 5 or More USD 795 USD 895 10 or More USD 395 USD 495 10 or More USD 695 USD 795

CHINA PHARMACEUTICAL & VIP ACCESS BIOTECH COMPANIES FOR PHARMA ATTEND FOR FREE* MANUFACTURERS 3 EASY WAYS TO REGISTER (FOR SPECIFIC JOB TITLES ONLY) *Organisers reserved rights to accept/reject complimentary pass applications submitted, also to request specific job functions as described below. This is to ensure you gain maximum benefit from conference Contact Miki Kong content and networking activities. +65 6508 2477

Registration Enquiry Email Brought to you by: [email protected] REGISTER NOW

Delegates who have successfully registered for the event will receive their Website Online Networking System (ONS) details to connect and network with other www.biopharmaproduction.com attendees nearer to the event date!

Connect with us: www.biopharmaproduction.com Informa Connect is a trading name of IBC Asia (S) Pte Ltd.